Related Experiment Video
Updated: May 23, 2026
07:37
Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
Published on: November 17, 2017
Next generation spray-dried on-demand plasma: A multicenter, randomized, dose-escalation, first-in-human safety study
Jose A Cancelas1,2, Lisa Buckley3, Susan F Leitman3
1Connell and O'Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Transfusion
|May 22, 2026
Summary
Spray-dried plasma (ODP) shows safety comparable to frozen plasma in a first-in-human trial. This novel product offers potential for improved prehospital resuscitation and emergency care.
Area of Science:
- Emergency Medicine
- Transfusion Medicine
- Biotechnology
Background:
- Prehospital plasma transfusion is vital for hemorrhagic shock but faces logistical challenges.
- Current plasma products require cold-chain storage, limiting availability.
- A novel spray-dried plasma (ODP) aims to overcome these limitations.
Purpose of the Study:
- To conduct the first-in-human clinical evaluation of spray-dried plasma (ODP).
- To assess the safety and tolerability of ODP in healthy volunteers.
- To compare ODP with standard frozen plasma (PF24) in a crossover study.
Main Methods:
- A dose-escalation study involving 24 healthy volunteers.
- Plasma was processed into both frozen (PF24) and spray-dried (ODP) forms.
- Participants received escalating doses of ODP or a comparison of ODP vs. PF24, followed by 28-day monitoring.
Main Results:
- Spray-dried plasma (ODP) demonstrated preserved protein content.
- All infusions were well-tolerated with no serious adverse events.
- Treatment-emergent adverse events were infrequent and comparable between ODP and PF24 groups.
Conclusions:
- Spray-dried plasma (ODP) exhibits a safety profile similar to standard frozen plasma.
- No thromboembolic events were observed, supporting its safety.
- ODP's stability and rapid reconstitution suggest potential for widespread prehospital and austere use.
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...